64排CT对急性冠脉综合征PCI术后患者两种剂量阿托伐他汀治疗效果的比较

目的:探究64排CT对急性冠脉综合征冠状动脉介入治疗术后患者两种剂量阿托伐他汀治疗效果。方法:选取某院收入的急性冠脉综合征行冠状动脉介入治疗患者50例,根据用药剂量的不同分为研究组与对比组,每组各25例。研究组在常规用药治疗基础上给予阿托伐他汀15mg,对比组在常规用药治疗基础上给予阿托伐他汀30mg。探究两组患者治疗前后血脂、超敏C反应蛋白与不同斑块CT值。结果:治疗后研究组总胆固醇、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇及超敏C反应蛋白均优于对比组,研究组脂质斑块与纤维斑块CT值均优于对比组,差异具有统计学意义P0.05。结论:小剂量的阿托伐他汀结合64排CT对急性冠脉综合征治疗效果显著,值得推广并运用。     

阿托伐他汀干预对急性冠状动脉综合征患者PCI术后粘附分子水平的影响

目的探讨不同剂量阿托伐他汀治疗对ACS（急性冠状动脉综合征）患者急诊经皮冠状动脉介入治疗（PCI）术后粘附分子水平的影响。方法入选88例ACS患者随机分为：A常规治疗组30人,B阿托伐他汀标准剂量组29人,C阿托伐他汀负荷剂量组29人。三组分别于术前、术后3、7、14天抽血,用ELISA法测定血清可溶性细胞间粘附分子（soluble intercellular adhesionmolecule-1,sICAM-1）、血管细胞粘附分子（soluble vascular cell adhesion molecule-1,sVCAM-1）水平。结果阿托伐他汀80mg,d组在治疗第7天,两种血清粘附分子水平显著低于阿托伐他汀10mg／d组,两组sICAM-1分别是（68．35±23．80）μg／L和（131．45±29．12）μg／L、sVCAM-1分别是（251．65±36．61）μg／L和（334．87±32．98）μg／L。此外,两组阿托伐他汀治疗剂量均显示可以显著减少两种粘附分子的水平（P〈0．05）,观察时段内各组对血脂水平影响无显著性差异（P〉0．05）结论阿托伐他汀治疗组比常规治疗组可以显著降低粘附分子水平,其中阿托伐他汀术后负荷剂量冲击治疗,较标准剂量更能显著降低血清粘附分子水平,从而抑制PCI术后的炎症反应的发生,减少术后再狭窄的发生。     

阿托伐他汀干预对急性冠状动脉综合征患者PCI术后粘附分子水平的影响

Objective To explore the impact of different dose atorvastatin on the adhesion molecules level in the acute coronary syndrome (ACS) patients who had received percutaneous coronary intervention (PCI). Methods Eighty-eight ACS patients were divided into three groups, group A (normal treatment group), group B (normal treatment plus atorvastatin 10mg per day) and group C (normal treatment plus atorvastatin 80mg per day). The patients in group B received atorvastatin 10 mg per day orally before PCI and after PCI subsequently, and the patients in group C received atorvastatin 80 mg per day orally before PCI and after PCI subsequently for three days, then the dose of atorvastatin was decrease to 10 mg per day. The concentrations of soluble intercellular adhesionmolecule-1 (sICAM-1) and soluble vascular cell adhesion molecule-1 (sVCAM-1) were detected before PCI and at the 3rd, 7th 14th day after PCI. Results At the 7th day, the concentrations of sICAM-1 and sVCAM-1 in group C were significantly lower than those in group B, which showed sICAM-1 (68.35±23.80) μg/L vs (131.45±29.12) μg/L and sVCAM-1 (251. 65±36.61)μg/L vs (334.87±32.98) μg/L, respectively. Compared to group A, the adhesion molecule level in group B and group C were significantly decreased (P<0.05) and had no obviously affect on blood fat level. Conclusion The treatment of atorvastatin could significantly decrease the adhesion molecules' level after PCI, which may play an important role in lowing inflammation and coronary artery restenosis after PCI.     

阿托伐他汀干预对急性冠状动脉综合征患者PCI术后粘附分子水平的影响

Objective To explore the impact of different dose atorvastatin on the adhesion molecules level in the acute coronary syndrome (ACS) patients who had received percutaneous coronary intervention (PCI). Methods Eighty-eight ACS patients were divided into three groups, group A (normal treatment group), group B (normal treatment plus atorvastatin 10mg per day) and group C (normal treatment plus atorvastatin 80mg per day). The patients in group B received atorvastatin 10 mg per day orally before PCI and after PCI subsequently, and the patients in group C received atorvastatin 80 mg per day orally before PCI and after PCI subsequently for three days, then the dose of atorvastatin was decrease to 10 mg per day. The concentrations of soluble intercellular adhesionmolecule-1 (sICAM-1) and soluble vascular cell adhesion molecule-1 (sVCAM-1) were detected before PCI and at the 3rd, 7th 14th day after PCI. Results At the 7th day, the concentrations of sICAM-1 and sVCAM-1 in group C were significantly lower than those in group B, which showed sICAM-1 (68.35±23.80) μg/L vs (131.45±29.12) μg/L and sVCAM-1 (251. 65±36.61)μg/L vs (334.87±32.98) μg/L, respectively. Compared to group A, the adhesion molecule level in group B and group C were significantly decreased (P<0.05) and had no obviously affect on blood fat level. Conclusion The treatment of atorvastatin could significantly decrease the adhesion molecules' level after PCI, which may play an important role in lowing inflammation and coronary artery restenosis after PCI.     

阿托伐他汀干预对急性冠状动脉综合征患者PCI术后粘附分子水平的影响

Objective To explore the impact of different dose atorvastatin on the adhesion molecules level in the acute coronary syndrome (ACS) patients who had received percutaneous coronary intervention (PCI). Methods Eighty-eight ACS patients were divided into three groups, group A (normal treatment group), group B (normal treatment plus atorvastatin 10mg per day) and group C (normal treatment plus atorvastatin 80mg per day). The patients in group B received atorvastatin 10 mg per day orally before PCI and after PCI subsequently, and the patients in group C received atorvastatin 80 mg per day orally before PCI and after PCI subsequently for three days, then the dose of atorvastatin was decrease to 10 mg per day. The concentrations of soluble intercellular adhesionmolecule-1 (sICAM-1) and soluble vascular cell adhesion molecule-1 (sVCAM-1) were detected before PCI and at the 3rd, 7th 14th day after PCI. Results At the 7th day, the concentrations of sICAM-1 and sVCAM-1 in group C were significantly lower than those in group B, which showed sICAM-1 (68.35±23.80) μg/L vs (131.45±29.12) μg/L and sVCAM-1 (251. 65±36.61)μg/L vs (334.87±32.98) μg/L, respectively. Compared to group A, the adhesion molecule level in group B and group C were significantly decreased (P<0.05) and had no obviously affect on blood fat level. Conclusion The treatment of atorvastatin could significantly decrease the adhesion molecules' level after PCI, which may play an important role in lowing inflammation and coronary artery restenosis after PCI.     

阿托伐他汀干预对急性冠状动脉综合征患者PCI术后粘附分子水平的影响

Objective To explore the impact of different dose atorvastatin on the adhesion molecules level in the acute coronary syndrome (ACS) patients who had received percutaneous coronary intervention (PCI). Methods Eighty-eight ACS patients were divided into three groups, group A (normal treatment group), group B (normal treatment plus atorvastatin 10mg per day) and group C (normal treatment plus atorvastatin 80mg per day). The patients in group B received atorvastatin 10 mg per day orally before PCI and after PCI subsequently, and the patients in group C received atorvastatin 80 mg per day orally before PCI and after PCI subsequently for three days, then the dose of atorvastatin was decrease to 10 mg per day. The concentrations of soluble intercellular adhesionmolecule-1 (sICAM-1) and soluble vascular cell adhesion molecule-1 (sVCAM-1) were detected before PCI and at the 3rd, 7th 14th day after PCI. Results At the 7th day, the concentrations of sICAM-1 and sVCAM-1 in group C were significantly lower than those in group B, which showed sICAM-1 (68.35±23.80) μg/L vs (131.45±29.12) μg/L and sVCAM-1 (251. 65±36.61)μg/L vs (334.87±32.98) μg/L, respectively. Compared to group A, the adhesion molecule level in group B and group C were significantly decreased (P<0.05) and had no obviously affect on blood fat level. Conclusion The treatment of atorvastatin could significantly decrease the adhesion molecules' level after PCI, which may play an important role in lowing inflammation and coronary artery restenosis after PCI.     

阿托伐他汀干预对急性冠状动脉综合征患者PCI术后粘附分子水平的影响

Objective To explore the impact of different dose atorvastatin on the adhesion molecules level in the acute coronary syndrome (ACS) patients who had received percutaneous coronary intervention (PCI). Methods Eighty-eight ACS patients were divided into three groups, group A (normal treatment group), group B (normal treatment plus atorvastatin 10mg per day) and group C (normal treatment plus atorvastatin 80mg per day). The patients in group B received atorvastatin 10 mg per day orally before PCI and after PCI subsequently, and the patients in group C received atorvastatin 80 mg per day orally before PCI and after PCI subsequently for three days, then the dose of atorvastatin was decrease to 10 mg per day. The concentrations of soluble intercellular adhesionmolecule-1 (sICAM-1) and soluble vascular cell adhesion molecule-1 (sVCAM-1) were detected before PCI and at the 3rd, 7th 14th day after PCI. Results At the 7th day, the concentrations of sICAM-1 and sVCAM-1 in group C were significantly lower than those in group B, which showed sICAM-1 (68.35±23.80) μg/L vs (131.45±29.12) μg/L and sVCAM-1 (251. 65±36.61)μg/L vs (334.87±32.98) μg/L, respectively. Compared to group A, the adhesion molecule level in group B and group C were significantly decreased (P<0.05) and had no obviously affect on blood fat level. Conclusion The treatment of atorvastatin could significantly decrease the adhesion molecules' level after PCI, which may play an important role in lowing inflammation and coronary artery restenosis after PCI.     

阿托伐他汀干预对急性冠状动脉综合征患者PCI术后粘附分子水平的影响

Objective To explore the impact of different dose atorvastatin on the adhesion molecules level in the acute coronary syndrome (ACS) patients who had received percutaneous coronary intervention (PCI). Methods Eighty-eight ACS patients were divided into three groups, group A (normal treatment group), group B (normal treatment plus atorvastatin 10mg per day) and group C (normal treatment plus atorvastatin 80mg per day). The patients in group B received atorvastatin 10 mg per day orally before PCI and after PCI subsequently, and the patients in group C received atorvastatin 80 mg per day orally before PCI and after PCI subsequently for three days, then the dose of atorvastatin was decrease to 10 mg per day. The concentrations of soluble intercellular adhesionmolecule-1 (sICAM-1) and soluble vascular cell adhesion molecule-1 (sVCAM-1) were detected before PCI and at the 3rd, 7th 14th day after PCI. Results At the 7th day, the concentrations of sICAM-1 and sVCAM-1 in group C were significantly lower than those in group B, which showed sICAM-1 (68.35±23.80) μg/L vs (131.45±29.12) μg/L and sVCAM-1 (251. 65±36.61)μg/L vs (334.87±32.98) μg/L, respectively. Compared to group A, the adhesion molecule level in group B and group C were significantly decreased (P<0.05) and had no obviously affect on blood fat level. Conclusion The treatment of atorvastatin could significantly decrease the adhesion molecules' level after PCI, which may play an important role in lowing inflammation and coronary artery restenosis after PCI.     

阿托伐他汀干预对急性冠状动脉综合征患者PCI术后粘附分子水平的影响

Objective To explore the impact of different dose atorvastatin on the adhesion molecules level in the acute coronary syndrome (ACS) patients who had received percutaneous coronary intervention (PCI). Methods Eighty-eight ACS patients were divided into three groups, group A (normal treatment group), group B (normal treatment plus atorvastatin 10mg per day) and group C (normal treatment plus atorvastatin 80mg per day). The patients in group B received atorvastatin 10 mg per day orally before PCI and after PCI subsequently, and the patients in group C received atorvastatin 80 mg per day orally before PCI and after PCI subsequently for three days, then the dose of atorvastatin was decrease to 10 mg per day. The concentrations of soluble intercellular adhesionmolecule-1 (sICAM-1) and soluble vascular cell adhesion molecule-1 (sVCAM-1) were detected before PCI and at the 3rd, 7th 14th day after PCI. Results At the 7th day, the concentrations of sICAM-1 and sVCAM-1 in group C were significantly lower than those in group B, which showed sICAM-1 (68.35±23.80) μg/L vs (131.45±29.12) μg/L and sVCAM-1 (251. 65±36.61)μg/L vs (334.87±32.98) μg/L, respectively. Compared to group A, the adhesion molecule level in group B and group C were significantly decreased (P<0.05) and had no obviously affect on blood fat level. Conclusion The treatment of atorvastatin could significantly decrease the adhesion molecules' level after PCI, which may play an important role in lowing inflammation and coronary artery restenosis after PCI.     

阿托伐他汀干预对急性冠状动脉综合征患者PCI术后粘附分子水平的影响

Objective To explore the impact of different dose atorvastatin on the adhesion molecules level in the acute coronary syndrome (ACS) patients who had received percutaneous coronary intervention (PCI). Methods Eighty-eight ACS patients were divided into three groups, group A (normal treatment group), group B (normal treatment plus atorvastatin 10mg per day) and group C (normal treatment plus atorvastatin 80mg per day). The patients in group B received atorvastatin 10 mg per day orally before PCI and after PCI subsequently, and the patients in group C received atorvastatin 80 mg per day orally before PCI and after PCI subsequently for three days, then the dose of atorvastatin was decrease to 10 mg per day. The concentrations of soluble intercellular adhesionmolecule-1 (sICAM-1) and soluble vascular cell adhesion molecule-1 (sVCAM-1) were detected before PCI and at the 3rd, 7th 14th day after PCI. Results At the 7th day, the concentrations of sICAM-1 and sVCAM-1 in group C were significantly lower than those in group B, which showed sICAM-1 (68.35±23.80) μg/L vs (131.45±29.12) μg/L and sVCAM-1 (251. 65±36.61)μg/L vs (334.87±32.98) μg/L, respectively. Compared to group A, the adhesion molecule level in group B and group C were significantly decreased (P<0.05) and had no obviously affect on blood fat level. Conclusion The treatment of atorvastatin could significantly decrease the adhesion molecules' level after PCI, which may play an important role in lowing inflammation and coronary artery restenosis after PCI.     

64排螺旋CT冠脉成像质量影响因素分析

目的 探讨不同护理干预条件下影响64排螺旋CT冠脉成像质量的因素.方法 138例行CT冠状动脉成像的患者,双盲法随机分为研究组72例和对照组66例,研究组检查前、中进行护理干预,包括心理干预、健康卫生宣教、屏气呼吸训练;对照组按常规操作进行.观测并记录两组患者检查时心理精神状态、心率控制时间、呼吸配合训练时间、扫描过程中不良反应的发生率及冠脉成像的质量.结果 研究组检查时焦虑与恐惧、服用药物的人数、心率控制时间及呼吸配合训练时间、检查中不良反应发生率、图像质量1~2级的比率及冠脉成像运动伪影的出现率均低于对照组(P<0.01,P<0.05).结论 严格有效细致的护理干预是64排螺旋CT冠状动脉成像检查成功的重要保障.     

64排螺旋CT冠状动脉造影对冠心病的诊断价值

目的探讨分析64排螺旋CT冠状动脉造影在冠心病诊断中的价值。方法随机选取经手术证实的42例冠心病患者,通过64排螺旋CT冠状动脉造影诊断。结果该组病灵敏度为95.24%、特异度97.62%、阳性预测值为88.10%、阴性预测值为92.86%。结论采用64排螺旋CT冠状动脉造影诊断冠心病是一种安全、快速、准确的检查方法,有很好的临床诊断价值,可以作为诊断冠心病的首选方法。     

造影剂注射速率对64层螺旋CT冠状动脉血管成像质量的影响

目的研究造影剂注射速率对64层螺旋CT冠状动脉血管成像质量的影响。方法 120例冠状动脉血管造影患者随机均分成三组,分别用4.5、5或5.5 ml/s的速率注射等量造影剂。应用64层螺旋CT进行扫描;采用团注实验测定延迟时间;分别在左冠发出层面横断面图像选择感兴趣区测量升、降主动脉衰减值(HU),利用多平面重建技术(MPR)于离出口约1 cm处的正交横断面图像测量心脏血管(左主干、前降支、回旋支及右冠状动脉)的衰减值。结果升、降主动脉及心脏血管三组间对比衰减均有统计学意义(P<0.01)。心脏血管对比衰减与体重(r=-0.722)、体重指数(BMI)(r=-0.599)明显相关(P<0.05)。以5 ml/s速率注射造影剂获得的图像质量优于其它两组(P<0.01)。结论在心脏CT血管造影(CTA)中在扫描条件及造影剂的碘浓度一致情况下,以5 ml/s注射速率给予造影剂可以获得良好的血管增强效果。     

护理干预在64排螺旋CT增强扫描中的应用效果观察

目的探讨护理干预在64排螺旋CT增强扫描中的临床应用价值。方法选取2011年3月至2012年3月期间在我院进行64排螺旋CT增强扫描的520例患者作为临床研究对象,随机将患者分成干预组和对照组,每组260例。两组患者在进行64排螺旋CT增强扫描检查的同时均采用一般常规护理,而干预组则在此基础上给予更为全面的护理干预方案,并对两组患者的临床疗效进行比较和分析。结果干预组患者与对照组相比,血压和心率处于正常状态的比率均显著提高,而处于波动状态的比率则显著降低,差别均具有统计学意义(P<0.05);轻度过敏的发生比率和过敏的总发生率均明显降低,并均呈现出显著性差异(P<0.05);心理状态明显改善,为0级的比率显著提高,差别具有统计学意义(P<0.05)。结论护理干预对于保证患者64排螺旋CT检查的顺利进行以及提高扫描质量均具有积极的临床意义。     

64层螺旋CT冠状动脉CTA显示心肌低灌注现象的分析

目的分析64层螺旋CT冠状动脉CTA的图像,总结显示心肌低强化现象的情况,并通过综合评价心肌强化情况与CTA冠状动脉血管图像,判断冠状动脉狭窄对于心肌血供影响的情况。方法回顾性分析2009年1月～2012年12月．在太原市中心医院进行64层螺旋CT冠状动脉CTA检查并行冠状动脉血管造影检查的39例临床可疑冠心病患者的CTA图像．心肌图像按17段分段法重建,对强化后的心肌密度进行测量,并记录CT值,以低于临近节段心肌密度30hu为低强化区域。结合冠状动脉血管造影检查结果,对于发现的冠状动脉狭窄段相对应的供血区心肌密度与相邻正常节段心肌密度进行两组均数分析。综合分析冠状动脉CTA血管及心肌图像．判断冠状动脉狭窄对心肌灌注造成的影响。结果39例患者均在1周内接受了冠状动脉CTA及血管造影检查。冠状动脉血管造影显示有意义的冠状动脉狭窄63段。39例患者的CT图像,经过重建,共得到663段心肌图像。其中1段心肌图像测量出脂肪密度,干扰低强化现象的分析,排除在外,其他662段心肌图像共显示低强化心肌87段。提示心肌灌注不足,其中71段显示为心内膜下低强化区,16段显示为透壁低强化区,低强化区平均CT值为（66．0±32．1）hu。其他各段心肌未见明显低强化区,CT值最低（95．2±25．8）hu,最高（122．1±26．6）hu,平均CT值为（108．18±8．83）hu。经过两组均数比较,t=5．150,P〈0．001,低强化区与正常强化区心肌CT值之间差异有统计学意义。结论在进行64层螺旋CT冠状动脉CTA检查过程中,综合评价冠状动脉血管及心肌强化CT图像,可以在一定程度上反映心肌血供情况,为临床治疗提供更多诊疗信息。     

64排螺旋CT冠状动脉造影检查在健康体检中的应用

目的评价64排螺旋CT冠状动脉造影检查（CCTA）在健康人群体检中的应用价值。方法应用东芝公司Aquilion64排螺旋CT对252例健康体检人群的冠状动脉主干及主要分支进行重建和分析,11例CCTA检查冠状动脉管腔重度狭窄受检者行动脉插管冠状动脉造影检查（DSA）,对比评价CCTA检查的准确性。结果CCTA检查冠状动脉病变检出率32．94％,随年龄增长而增加,与DSA有很好的一致性。结论CCTA无创、快速、精确、费用比DsA相对低廉等优越性可作为高端健康体检筛选冠心病的重要手段,为健康人群体检保驾护航。     

64层螺旋CT薄层扫描在肝癌诊断中的应用价值

目的探讨64层螺旋CT薄层扫描在原发性肝癌诊断中的应用价值。方法回顾性分析32例经临床及手术病理证实的原发性肝癌平扫及增强三期的影像表现。结果 77.8%的癌灶在肝动脉期呈现高密度强化表现,充分说明螺旋CT扫描可反映肝癌的血供特点,门脉期有41.7%的病灶呈现等密度,63.9%病灶呈现低密度影像,也反映了肝细胞癌"速升速降"的增强变化特点,可作为诊断原发性肝癌最有价值的征象。结论螺旋薄层扫描可充分反映原发性肝癌的特征,对肝癌的检出和定性准确率的提高有重要价值。     

64排螺旋CT对正常成年人胰腺影像解剖学研究

目的:探讨正常成年人胰腺影像解剖学的差异性,为影像学诊断及临床诊治提供解剖学影像资料。方法:通过64排螺旋CT对200例正常成年人胰腺进行平扫及增强扫描,并通过多平面重建、容积再现和最大密度投影等技术重建,观察胰腺与脾脏的关系以及胰腺影像解剖学差异。结果:重建胰腺形态直观,轮廓光滑123例,分叶64例。胰尾与脾门紧贴52例,分开125例,胰尾越过脾门10例。胰腺平均体积(122.43±21.08)cm3,胰腺体积与性别有显著差异,男性组大于女性组(P<0.05)。结论:成人胰腺体积与年龄、性别相关,胰腺萎缩多发生于老年人,男性大于女性,64排螺旋CT扫描对胰腺与周围毗邻关系鉴别诊断有临床指导意义。     

下肢动脉64层螺旋CT血管成像技术的应用方法

目的探讨64层螺旋CT在下肢动脉病变的中应用价值。方法回顾性分析我院2011年9月—2012年7月收治的36例下肢动脉病变患者的临床资料,均行血管造影及及64层螺旋CT血管成像术检查,对64层螺旋CT成像术在下肢动脉病变中的应用价值进行评价。结果 36例患者CTA均清晰显示检查范围内动脉血管影像,图像分辨率较高,可显示各级主要分支血管,与DSA诊断结果进行比较差异无统计学意义(P>0.05)。结论 64层螺旋CT血管成像技术是一种可靠、快捷、无创的下肢血管检查方法,值得在临床推广。     

64排螺旋CT对青壮年冠状动脉病变的诊断价值

目的 探讨及评估64排螺旋CT冠状动脉成像对青壮年（年龄≤50岁）冠状动脉病变的诊断价值.方法 回顾性分析156例小于等于50岁的临床可疑冠心病患者的冠状动脉CTA检查资料.对所有原始资料采用容积再现、最大密度投影、多平面重组、曲面重建进行图像后处理,显示冠状动脉主干及主要分支.结果 156例中检出冠状动脉心肌桥38例（24%）,冠状动脉硬化53例（34%）,冠状动脉起源异常4例（3%）.结论 64排螺旋CT冠状动脉成像是一种可靠的、无创性的检查方法,对于青壮年的冠状动脉病变是一种安全的筛查方法.